A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study of the Efficacy and Safety of Cobiprostone for the Prevention of NSAID-Induced Gastroduodenal Injury in Patients With Osteoarthritis and/or Rheumatoid Arthritis Patients.

Trial Profile

A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study of the Efficacy and Safety of Cobiprostone for the Prevention of NSAID-Induced Gastroduodenal Injury in Patients With Osteoarthritis and/or Rheumatoid Arthritis Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2010

At a glance

  • Drugs Cobiprostone (Primary)
  • Indications NSAID-induced gastrointestinal damage
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2010 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 03 May 2010 Results have been presented at DDW 2010.
    • 02 Jul 2009 Top-line results presented in a Sucampo Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top